Aimmune Therapeutics Inc Has More Gas To Decrease After Today’s Bearish Options Activity

 Aimmune Therapeutics Inc Has More Gas To Decrease After Today's Bearish Options Activity

In today’s session Aimmune Therapeutics Inc (AIMT) recorded an unusually high (185) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious AIMT decrease. With 185 contracts traded and 204 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: AIMT161216P00022500 closed last at: $1 or 66.7% up. About 28,886 shares traded hands. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 76.85% since April 22, 2016 and is uptrending. It has outperformed by 71.44% the S&P500.

Analysts await Aimmune Therapeutics Inc (NASDAQ:AIMT) to report earnings on March, 2. They expect $-0.47 earnings per share, down 20.51% or $0.08 from last year’s $-0.39 per share. After $-0.53 actual earnings per share reported by Aimmune Therapeutics Inc for the previous quarter, Wall Street now forecasts -11.32% EPS growth.

Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage

Out of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aimmune Therapeutics has been the topic of 5 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Piper Jaffray maintained it with “Overweight” rating and $38.0 target price in Tuesday, November 17 report. The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) earned “Mkt Outperform” rating by JMP Securities on Monday, September 26. The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) has “Buy” rating given on Monday, August 31 by Bank of America. The firm has “Overweight” rating by Piper Jaffray given on Monday, August 31. Credit Suisse initiated the shares of AIMT in a report on Monday, August 31 with “Outperform” rating.

According to Zacks Investment Research, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.”

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company has a market cap of $1.05 billion. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy , is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It currently has negative earnings. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101.

AIMT Company Profile

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, incorporated on June 24, 2011, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

More notable recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 12, 2015, also Quotes.Wsj.com with their article: “News Aimmune Therapeutics Inc.AIMT” published on July 31, 2015, Businesswire.com published: “Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health …” on November 04, 2016. More interesting news about Aimmune Therapeutics Inc (NASDAQ:AIMT) were released by: Fiercebiotech.com and their article: “Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101” published on June 18, 2015 as well as Businesswire.com‘s news article titled: “Aimmune Therapeutics Completes and Exceeds North American Enrollment Target …” with publication date: September 20, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment